What is Brilinta ticagrelor used for?
Ticagrelor is used along with low-dose aspirin to help prevent heart attack and stroke in people with a history of heart disease, stroke, or at increased risk for heart disease or stroke (for example, due to diabetes, history of transient ischemic attack-TIA).
What are the indications for Brilinta?
INDICATIONS. BRILINTA is indicated to reduce the risk of cardiovascular death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction.
When should you take Brilinta?
Take Brilinta around the same time every day (for example, one tablet in the morning and one in the evening).
Who needs Brilinta?
If you’re at risk for blood clots, your doctor may prescribe Brilinta for you. It’s used to lower the risk of some heart and blood clot problems in certain adults who: have acute coronary syndrome (ACS) or have had a heart attack. have ACS and have had a stent placed in one or more heart blood vessels.
What does ticagrelor do for the heart?
The clot can stop blood flowing to the heart or brain and cause a heart attack or stroke. If you take it every day, ticagrelor stops platelets from clumping together to form unwanted blood clots, and helps to prevent heart attacks and strokes.
What does BRILINTA do to platelets?
Brilinta prevents platelets in your blood from sticking together to form an unwanted blood clot that could block an artery. Platelets are tiny blood cells that clump and stick together to repair a damaged blood vessel. Brilinta keeps blood flowing smoothly.
Does brilinta raise blood pressure?
Brilinta may reduce your risk for heart attack and stroke, but may raise your risk of some problems including excessive bleeding, stomach upset, headaches, dizziness, nausea, irregular heartbeat (atrial fibrillation), high or low blood pressure, chest pain, diarrhea, back pain, fatigue and shortness of breath.
What are the side effects of brilinta 90 mg?
Common side effects of Brilinta include:
- bruising.
- bleeding more easily.
- nosebleeds.
- headache.
- dizziness.
- cough.
- nausea.
- diarrhea.
Can I take BRILINTA once a day?
Brilinta comes as tablets that are taken twice a day, while Effient comes as tablets that are taken once a day. Both Brilinta and Effient should each be taken with daily aspirin.
Does BRILINTA lower heart rate?
Other common side effects with BRILINTA include dizziness, nausea, diarrhea, slow heartbeat rate, rash, and allergic reactions including swelling of the face, throat, lips, tongue, hands, or feet. These are not all the possible side effects of BRILINTA.
When is the best time to take ticagrelor?
When you start taking ticagrelor, you’ll take 1 dose on your first day. After this, most people take ticagrelor twice a day, usually once in the morning and once in the evening. You can take ticagrelor with or without food. If you’re taking melt in the mouth tablets, put the tablet on your tongue and let it dissolve.
Is it necessary to take aspirin with BRILINTA?
BRILINTA is an oral antiplatelet that can help protect you from having another heart attack. BRILINTA is taken with a low-dose aspirin, no more than 100 mg, as it affects how well BRILINTA works.
How much does Brilinta cost?
Brilinta can cost around $427 for a supply of 60, 90 mg tablets, depending on the pharmacy. Prices, on average, are similar for the 90 mg Brilinta oral tablets.
What is Brilinta used for?
Brilinta is the brand name of the generic prescription drug ticagrelor. It’s used, along with low doses of aspirin, to reduce the risk of a serious heart problem or stroke in people who’ve already had a heart attack or experience chest pain.
Is Brilinta a beta blocker?
Brilinta is not a beta blocker. Brilinta belongs to a group of medicines called antiplatelet medicines. The information given above is for Ticagrelor which is the active ingredient of Brilinta.
Is there a generic Brilinta?
Brilinta is the trade name used for a drug which contains ticagrelor. Under the generic name of Ticagrelor, its trade name is Brilique and Possia in the EU. It inhibits platelet aggregation, which causes blood clotting in the blood vessels. It was approved for use in Europe in 2010 and by the US Food and Drug Administration in 2011.